Mechanisms of immunotherapy resistance: lessons from glioblastoma

Christopher M. Jackson, John Choi, Michael Lim

Research output: Contribution to journalReview article

Abstract

Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than 2 years despite surgical resection, radiation, and chemotherapy. GBM’s rapid progression, resistance to therapy, and inexorable recurrence have been attributed to several factors, including its rapid growth rate, its molecular heterogeneity, its propensity to infiltrate vital brain structures, the regenerative capacity of treatment-resistant cancer stem cells, and challenges in achieving high concentrations of chemotherapeutic agents in the central nervous system. Escape from immunosurveillance is increasingly recognized as a landmark event in cancer biology. Translation of this framework to clinical oncology has positioned immunotherapy as a pillar of cancer treatment. Amid the bourgeoning successes of cancer immunotherapy, GBM has emerged as a model of resistance to immunotherapy. Here we review the mechanisms of immunotherapy resistance in GBM and discuss how insights into GBM–immune system interactions might inform the next generation of immunotherapeutics for GBM and other resistant pathologies.

Original languageEnglish (US)
JournalNature Immunology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Glioblastoma
Immunotherapy
Central Nervous System Agents
Immunologic Monitoring
Neoplasms
Medical Oncology
Neoplastic Stem Cells
Brain Neoplasms
Therapeutics
Radiation
Pathology
Recurrence
Drug Therapy
Brain
Growth

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Mechanisms of immunotherapy resistance : lessons from glioblastoma. / Jackson, Christopher M.; Choi, John; Lim, Michael.

In: Nature Immunology, 01.01.2019.

Research output: Contribution to journalReview article

@article{1034d0b3e823431b82b2297ebe9aa67f,
title = "Mechanisms of immunotherapy resistance: lessons from glioblastoma",
abstract = "Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than 2 years despite surgical resection, radiation, and chemotherapy. GBM’s rapid progression, resistance to therapy, and inexorable recurrence have been attributed to several factors, including its rapid growth rate, its molecular heterogeneity, its propensity to infiltrate vital brain structures, the regenerative capacity of treatment-resistant cancer stem cells, and challenges in achieving high concentrations of chemotherapeutic agents in the central nervous system. Escape from immunosurveillance is increasingly recognized as a landmark event in cancer biology. Translation of this framework to clinical oncology has positioned immunotherapy as a pillar of cancer treatment. Amid the bourgeoning successes of cancer immunotherapy, GBM has emerged as a model of resistance to immunotherapy. Here we review the mechanisms of immunotherapy resistance in GBM and discuss how insights into GBM–immune system interactions might inform the next generation of immunotherapeutics for GBM and other resistant pathologies.",
author = "Jackson, {Christopher M.} and John Choi and Michael Lim",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41590-019-0433-y",
language = "English (US)",
journal = "Nature Immunology",
issn = "1529-2908",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Mechanisms of immunotherapy resistance

T2 - lessons from glioblastoma

AU - Jackson, Christopher M.

AU - Choi, John

AU - Lim, Michael

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than 2 years despite surgical resection, radiation, and chemotherapy. GBM’s rapid progression, resistance to therapy, and inexorable recurrence have been attributed to several factors, including its rapid growth rate, its molecular heterogeneity, its propensity to infiltrate vital brain structures, the regenerative capacity of treatment-resistant cancer stem cells, and challenges in achieving high concentrations of chemotherapeutic agents in the central nervous system. Escape from immunosurveillance is increasingly recognized as a landmark event in cancer biology. Translation of this framework to clinical oncology has positioned immunotherapy as a pillar of cancer treatment. Amid the bourgeoning successes of cancer immunotherapy, GBM has emerged as a model of resistance to immunotherapy. Here we review the mechanisms of immunotherapy resistance in GBM and discuss how insights into GBM–immune system interactions might inform the next generation of immunotherapeutics for GBM and other resistant pathologies.

AB - Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than 2 years despite surgical resection, radiation, and chemotherapy. GBM’s rapid progression, resistance to therapy, and inexorable recurrence have been attributed to several factors, including its rapid growth rate, its molecular heterogeneity, its propensity to infiltrate vital brain structures, the regenerative capacity of treatment-resistant cancer stem cells, and challenges in achieving high concentrations of chemotherapeutic agents in the central nervous system. Escape from immunosurveillance is increasingly recognized as a landmark event in cancer biology. Translation of this framework to clinical oncology has positioned immunotherapy as a pillar of cancer treatment. Amid the bourgeoning successes of cancer immunotherapy, GBM has emerged as a model of resistance to immunotherapy. Here we review the mechanisms of immunotherapy resistance in GBM and discuss how insights into GBM–immune system interactions might inform the next generation of immunotherapeutics for GBM and other resistant pathologies.

UR - http://www.scopus.com/inward/record.url?scp=85069937645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069937645&partnerID=8YFLogxK

U2 - 10.1038/s41590-019-0433-y

DO - 10.1038/s41590-019-0433-y

M3 - Review article

C2 - 31358997

AN - SCOPUS:85069937645

JO - Nature Immunology

JF - Nature Immunology

SN - 1529-2908

ER -